Exact Mass: 492.253656
Exact Mass Matches: 492.253656
Found 371 metabolites which its exact mass value is equals to given mass value 492.253656
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Bezitramide
C31H32N4O2 (492.25251319999995)
N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AC - Diphenylpropylamine derivatives D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics
Lurasidone
PA(2:0/18:1(12Z)-O(9S,10R))
PA(2:0/18:1(12Z)-O(9S,10R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/18:1(12Z)-O(9S,10R)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 9,10-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(18:1(12Z)-O(9S,10R)/2:0)
PA(18:1(12Z)-O(9S,10R)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(12Z)-O(9S,10R)/2:0), in particular, consists of one chain of one 9,10-epoxy-octadecenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(2:0/18:1(9Z)-O(12,13))
PA(2:0/18:1(9Z)-O(12,13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/18:1(9Z)-O(12,13)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 12,13-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
PA(18:1(9Z)-O(12,13)/2:0)
PA(18:1(9Z)-O(12,13)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(9Z)-O(12,13)/2:0), in particular, consists of one chain of one 12,13-epoxy-octadecenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).
Kushenol B
Kushenol B is a member of flavanones. Kushenol B is a natural product found in Sophora and Sophora flavescens with data available.
Kadlongilactone B
A hexacyclic triterpenoid isolated from the leaves and stems of Kadsura longipedunculata and has been found to exhibit cytotoxicity aganist human tumour cells.
Macaflavanone G
A trihydroxyflavanone that is (2S)-flavanone substituted by hydroxy groups at positions 5, 7 and 4, a prenyl group at position 6 and a (2S)-2-methyl-2-(4-methylpent-3-en-1-yl)tetrahydro-2H-pyran ring fused across positions 2 and 3. Isolated from the leaves of Macaranga tanarius, it exhibits antineoplastic activity.
2,4,6,3-Tetrahydroxy-3-geranyl-6,6-dimethylpyrano[2,3:4,5]dihydrochalcone
Propolin G
(-)-Nymphaeol C|(-)-Nymphaeol-C|5,7,3,4-tetrahydroxy-6-(3,3-dimethylallyl)-2-C-geranylflavanone|5,7,3,4-tetrahydroxy-6-(3,3-dimethylallyl)-2-geranylflavanone|Nymphaeol C|nymphaeol-C|propolin G
(E)-1,3-dihydroxy-6,7-dimethoxy-2-(3-methylbut-2-enyl)-8-(3,7-dimethyl-2,6-octadienyl)xanthone|6-O-methylcowanin
lespeflorin B4
A trihydroxyflavanone that is (2S)-flavanone substituted by hydroxy groups at positions 3, 5, 7 and 4 and prenyl groups at positions 6, 8 and 3. Isolated from the roots of Lespedeza floribunda, it acts as a melanin synthesis inhibitor.
Sanggenol P
5,7,2,4-tetrahydroxyl-6,8,5-tri-(gamma,gamma-dimethylallyl)isoflavanone|6,8,5-tri-(gamma,gamma-dimethylallyl)dalbergioidin|ormosinol
tetradehydro-17,4,5,6 3alpha cinchophylline
C31H32N4O2 (492.25251319999995)
Cys Lys Arg Ser
Cys Lys Ser Arg
Cys Arg Lys Ser
Cys Arg Ser Lys
Cys Ser Lys Arg
Cys Ser Arg Lys
Asp Phe Ile Val
Asp Phe Leu Val
Asp Phe Val Ile
Asp Phe Val Leu
Asp Ile Phe Val
Asp Ile Val Phe
Asp Leu Phe Val
Asp Leu Val Phe
Asp Val Phe Ile
Asp Val Phe Leu
Asp Val Ile Phe
Asp Val Leu Phe
Glu Phe Val Val
Glu Val Phe Val
Glu Val Val Phe
Phe Asp Ile Val
Phe Asp Leu Val
Phe Asp Val Ile
Phe Asp Val Leu
Phe Glu Val Val
Phe Gly Asn Arg
C21H32N8O6 (492.24446919999997)
Phe Gly Arg Asn
C21H32N8O6 (492.24446919999997)
Phe Ile Asp Val
Phe Ile Val Asp
Phe Leu Asp Val
Phe Leu Val Asp
Phe Asn Gly Arg
C21H32N8O6 (492.24446919999997)
Phe Asn Arg Gly
C21H32N8O6 (492.24446919999997)
Phe Arg Gly Asn
C21H32N8O6 (492.24446919999997)
Phe Arg Asn Gly
C21H32N8O6 (492.24446919999997)
Phe Val Asp Ile
Phe Val Asp Leu
Phe Val Glu Val
Phe Val Ile Asp
Phe Val Leu Asp
Phe Val Val Glu
Gly Phe Asn Arg
C21H32N8O6 (492.24446919999997)
Gly Phe Arg Asn
C21H32N8O6 (492.24446919999997)
Gly Asn Phe Arg
C21H32N8O6 (492.24446919999997)
Gly Asn Arg Phe
C21H32N8O6 (492.24446919999997)
Gly Arg Phe Asn
C21H32N8O6 (492.24446919999997)
Gly Arg Asn Phe
C21H32N8O6 (492.24446919999997)
His His Ile Ser
C21H32N8O6 (492.24446919999997)
His His Leu Ser
C21H32N8O6 (492.24446919999997)
His His Ser Ile
C21H32N8O6 (492.24446919999997)
His His Ser Leu
C21H32N8O6 (492.24446919999997)
His His Thr Val
C21H32N8O6 (492.24446919999997)
His His Val Thr
C21H32N8O6 (492.24446919999997)
His Ile His Ser
C21H32N8O6 (492.24446919999997)
His Ile Ser His
C21H32N8O6 (492.24446919999997)
His Leu His Ser
C21H32N8O6 (492.24446919999997)
His Leu Ser His
C21H32N8O6 (492.24446919999997)
His Ser His Ile
C21H32N8O6 (492.24446919999997)
His Ser His Leu
C21H32N8O6 (492.24446919999997)
His Ser Ile His
C21H32N8O6 (492.24446919999997)
His Ser Leu His
C21H32N8O6 (492.24446919999997)
His Thr His Val
C21H32N8O6 (492.24446919999997)
His Thr Val His
C21H32N8O6 (492.24446919999997)
His Val His Thr
C21H32N8O6 (492.24446919999997)
His Val Thr His
C21H32N8O6 (492.24446919999997)
Ile Asp Phe Val
Ile Asp Val Phe
Ile Phe Asp Val
Ile Phe Val Asp
Ile His His Ser
C21H32N8O6 (492.24446919999997)
Ile His Ser His
C21H32N8O6 (492.24446919999997)
Ile Met Met Val
C21H40N4O5S2 (492.24399900000003)
Ile Met Val Met
C21H40N4O5S2 (492.24399900000003)
Ile Pro Thr Tyr
Ile Pro Tyr Thr
Ile Ser His His
C21H32N8O6 (492.24446919999997)
Ile Thr Pro Tyr
Ile Thr Tyr Pro
Ile Val Asp Phe
Ile Val Phe Asp
Ile Val Met Met
C21H40N4O5S2 (492.24399900000003)
Ile Tyr Pro Thr
Ile Tyr Thr Pro
Lys Cys Arg Ser
Lys Cys Ser Arg
Lys Arg Cys Ser
Lys Arg Ser Cys
Lys Ser Cys Arg
Lys Ser Arg Cys
Leu Asp Phe Val
Leu Asp Val Phe
Leu Phe Asp Val
Leu Phe Val Asp
Leu His His Ser
C21H32N8O6 (492.24446919999997)
Leu His Ser His
C21H32N8O6 (492.24446919999997)
Leu Met Met Val
C21H40N4O5S2 (492.24399900000003)
Leu Met Val Met
C21H40N4O5S2 (492.24399900000003)
Leu Pro Thr Tyr
Leu Pro Tyr Thr
Leu Ser His His
C21H32N8O6 (492.24446919999997)
Leu Thr Pro Tyr
Leu Thr Tyr Pro
Leu Val Asp Phe
Leu Val Phe Asp
Leu Val Met Met
C21H40N4O5S2 (492.24399900000003)
Leu Tyr Pro Thr
Leu Tyr Thr Pro
Met Ile Met Val
C21H40N4O5S2 (492.24399900000003)
Met Ile Val Met
C21H40N4O5S2 (492.24399900000003)
Met Leu Met Val
C21H40N4O5S2 (492.24399900000003)
Met Leu Val Met
C21H40N4O5S2 (492.24399900000003)
Met Met Ile Val
C21H40N4O5S2 (492.24399900000003)
Met Met Leu Val
C21H40N4O5S2 (492.24399900000003)
Met Met Val Ile
C21H40N4O5S2 (492.24399900000003)
Met Met Val Leu
C21H40N4O5S2 (492.24399900000003)
Met Val Ile Met
C21H40N4O5S2 (492.24399900000003)
Met Val Leu Met
C21H40N4O5S2 (492.24399900000003)
Met Val Met Ile
C21H40N4O5S2 (492.24399900000003)
Met Val Met Leu
C21H40N4O5S2 (492.24399900000003)
Asn Phe Gly Arg
C21H32N8O6 (492.24446919999997)
Asn Phe Arg Gly
C21H32N8O6 (492.24446919999997)
Asn Gly Phe Arg
C21H32N8O6 (492.24446919999997)
Asn Gly Arg Phe
C21H32N8O6 (492.24446919999997)
Asn Arg Phe Gly
C21H32N8O6 (492.24446919999997)
Asn Arg Gly Phe
C21H32N8O6 (492.24446919999997)
Pro Ile Thr Tyr
Pro Ile Tyr Thr
Pro Leu Thr Tyr
Pro Leu Tyr Thr
Pro Thr Ile Tyr
Pro Thr Leu Tyr
Pro Thr Tyr Ile
Pro Thr Tyr Leu
Pro Tyr Ile Thr
Pro Tyr Leu Thr
Pro Tyr Thr Ile
Pro Tyr Thr Leu
Arg Cys Lys Ser
Arg Cys Ser Lys
Arg Phe Gly Asn
C21H32N8O6 (492.24446919999997)
Arg Phe Asn Gly
C21H32N8O6 (492.24446919999997)
Arg Gly Phe Asn
C21H32N8O6 (492.24446919999997)
Arg Gly Asn Phe
C21H32N8O6 (492.24446919999997)
Arg Lys Cys Ser
Arg Lys Ser Cys
Arg Asn Phe Gly
C21H32N8O6 (492.24446919999997)
Arg Asn Gly Phe
C21H32N8O6 (492.24446919999997)
Arg Ser Cys Lys
Arg Ser Lys Cys
Ser Cys Lys Arg
Ser Cys Arg Lys
Ser His His Ile
C21H32N8O6 (492.24446919999997)
Ser His His Leu
C21H32N8O6 (492.24446919999997)
Ser His Ile His
C21H32N8O6 (492.24446919999997)
Ser His Leu His
C21H32N8O6 (492.24446919999997)
Ser Ile His His
C21H32N8O6 (492.24446919999997)
Ser Lys Cys Arg
Ser Lys Arg Cys
Ser Leu His His
C21H32N8O6 (492.24446919999997)
Ser Arg Cys Lys
Ser Arg Lys Cys
Thr His His Val
C21H32N8O6 (492.24446919999997)
Thr His Val His
C21H32N8O6 (492.24446919999997)
Thr Ile Pro Tyr
Thr Ile Tyr Pro
Thr Leu Pro Tyr
Thr Leu Tyr Pro
Thr Pro Ile Tyr
Thr Pro Leu Tyr
Thr Pro Tyr Ile
Thr Pro Tyr Leu
Thr Val His His
C21H32N8O6 (492.24446919999997)
Thr Tyr Ile Pro
Thr Tyr Leu Pro
Thr Tyr Pro Ile
Thr Tyr Pro Leu
Val Asp Phe Ile
Val Asp Phe Leu
Val Asp Ile Phe
Val Asp Leu Phe
Val Glu Phe Val
Val Glu Val Phe
Val Phe Asp Ile
Val Phe Asp Leu
Val Phe Glu Val
Val Phe Ile Asp
Val Phe Leu Asp
Val Phe Val Glu
Val His His Thr
C21H32N8O6 (492.24446919999997)
Val His Thr His
C21H32N8O6 (492.24446919999997)
Val Ile Asp Phe
Val Ile Phe Asp
Val Ile Met Met
C21H40N4O5S2 (492.24399900000003)
Val Leu Asp Phe
Val Leu Phe Asp
Val Leu Met Met
C21H40N4O5S2 (492.24399900000003)
Val Met Ile Met
C21H40N4O5S2 (492.24399900000003)
Val Met Leu Met
C21H40N4O5S2 (492.24399900000003)
Val Met Met Ile
C21H40N4O5S2 (492.24399900000003)
Val Met Met Leu
C21H40N4O5S2 (492.24399900000003)
Val Thr His His
C21H32N8O6 (492.24446919999997)
Val Val Glu Phe
Val Val Phe Glu
Tyr Ile Pro Thr
Tyr Ile Thr Pro
Tyr Leu Pro Thr
Tyr Leu Thr Pro
Tyr Pro Ile Thr
Tyr Pro Leu Thr
Tyr Pro Thr Ile
Tyr Pro Thr Leu
Tyr Thr Ile Pro
Tyr Thr Leu Pro
Tyr Thr Pro Ile
Tyr Thr Pro Leu
29-demethylgeodisterol-O-sulfite
C27H40O6S (492.25454600000006)
lurasidone
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AE - Indole derivatives D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist C78272 - Agent Affecting Nervous System > C66883 - Dopamine Antagonist
Bezitramide
C31H32N4O2 (492.25251319999995)
N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AC - Diphenylpropylamine derivatives D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent D002491 - Central Nervous System Agents > D000700 - Analgesics
[(2R)-1-acetyloxy-3-phosphonooxypropan-2-yl] (Z)-11-(3-pentyloxiran-2-yl)undec-9-enoate
[(2R)-2-acetyloxy-3-phosphonooxypropyl] (Z)-11-(3-pentyloxiran-2-yl)undec-9-enoate
Nymphaeol C
A tetrahydroxyflavanone that is (2S)-flavanone substituted by hydroxy group at positions 5, 7, 3 and 4, a geranyl group at position 2 and a prenyl group at position 6. Isolated from Macaranga tanarius and propolis collected in Okinawa, it exhibits radical scavenging activity.
schizolaenone B
A tetrahydroxyflavanone that is (2S)-flavanone substituted by hydroxy groups at positions 5, 7, 4 and 5, a geranyl group at position 3 and a prenyl group at position 6. Isolated from Schizolaena hystrix, it exhibits cytotoxicity against ovarian cancer cell line.
Asp-Leu-Phe-Val
A tetrapeptide composed of L-aspartic acid, L-leucine, L-phenylalanine and L-valine joined in sequence by peptide linkages.
3-[[4-(diphenylmethyl)-1-piperazinyl]-oxomethyl]-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-12-one
C31H32N4O2 (492.25251319999995)
3-[(1-tert-butyl-5-tetrazolyl)-[2-furanylmethyl(2-oxolanylmethyl)amino]methyl]-6-methoxy-1H-quinolin-2-one
(2S,3S,3aR,9bR)-N1-cyclopentyl-N2-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide
(2R,3R,3aS,9bS)-N1-cyclopentyl-N2-(cyclopropylmethyl)-3-(hydroxymethyl)-6-oxo-7-(5-pyrimidinyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide
(1S)-1-(hydroxymethyl)-7-methoxy-1-[oxo(2-pyrazinyl)methyl]-N-propan-2-yl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
(1R)-2-(cyclopropylmethyl)-N-(3-fluorophenyl)-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
(1S)-2-(cyclopropylmethyl)-N-(3-fluorophenyl)-1-(hydroxymethyl)-7-methoxy-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
(1R)-1-(hydroxymethyl)-7-methoxy-1-[oxo(2-pyrazinyl)methyl]-N-propan-2-yl-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
(2R,3R,3aS,9bS)-1-N-cyclopentyl-3-(hydroxymethyl)-6-oxo-7-[(E)-prop-1-enyl]-2-N-(pyrimidin-4-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide
(2S,3S,3aR,9bR)-1-N-cyclopentyl-3-(hydroxymethyl)-6-oxo-7-[(E)-prop-1-enyl]-2-N-(pyrimidin-4-ylmethyl)-3,3a,4,9b-tetrahydro-2H-pyrrolo[2,3-a]indolizine-1,2-dicarboxamide
5',9,9,14,18-pentamethyl-3'h-8,20,24-trioxaspiro[hexacyclo[19.2.1.0²,¹³.0⁴,¹⁰.0¹⁴,²².0¹⁷,²²]tetracosane-19,2'-pyran]-2(13),3,5-triene-6',7-dione
3,8,9-trihydroxy-4-[4-hydroxy-3-(hydroxymethyl)but-2-en-1-yl]-6-methyl-4,7-bis(3-methylbut-2-en-1-yl)anthracen-1-one
(1s,10r,14s,17r,18s,19s,21r,22s)-5',9,9,14,18-pentamethyl-3'h-8,20,24-trioxaspiro[hexacyclo[19.2.1.0²,¹³.0⁴,¹⁰.0¹⁴,²².0¹⁷,²²]tetracosane-19,2'-pyran]-2(13),3,5-triene-6',7-dione
(3ar,6s,6ar,10s,12r,13r,15as)-1,6,12,13-tetrahydroxy-3-(1h-indol-3-ylmethyl)-4,5,10-trimethyl-3h,3ah,6h,6ah,9h,10h,11h,12h,13h,14h-cycloundeca[d]isoindol-15-one
2-[2-(3,7-dimethylocta-2,6-dien-1-yl)-3,4-dihydroxyphenyl]-5,7-dihydroxy-6-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
(2s)-2-[5-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxyphenyl]-5,7-dihydroxy-8-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
(1s,1'r,2s,3's,5s,6's,9s,10's,11'r,12r,14s)-2-hydroxy-2,3',11,12'-tetramethyl-6-methylidene-2',8,9'-trioxaspiro[tetracyclo[10.2.1.0¹,¹⁰.0⁵,⁹]pentadecane-14,7'-tetracyclo[9.3.0.0¹,³.0⁶,¹⁰]tetradecane]-10,12'-diene-7,8'-dione
(2s)-5,7-dihydroxy-2-[(2r)-8-hydroxy-2-methyl-2-(4-methylpent-3-en-1-yl)-3,4-dihydro-1-benzopyran-6-yl]-6-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
(1r,2s,13r,15r,18s,23s,24s)-13-hydroxy-1,6,6,20,24-pentamethyl-7,22-dioxahexacyclo[13.12.0.0²,¹³.0⁵,¹¹.0¹⁶,²⁵.0¹⁸,²³]heptacosa-9,11,16(25),19-tetraene-8,21,26-trione
(10s)-4,10,15-trihydroxy-13-methyl-5,7-bis(3-methylbut-2-en-1-yl)-12-[(3-methylbut-2-en-1-yl)oxy]-9-oxatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,12,14-hexaen-2-one
artemyriantholide a
{"Ingredient_id": "HBIN016967","Ingredient_name": "artemyriantholide a","Alias": "NA","Ingredient_formula": "C30H36O6","Ingredient_Smile": "CC1=CCC23C1C4C(CCC2(O3)C)C5(CC6CC57C(=C6C)C8C(CCC7(C)O)C(=C)C(=O)O8)C(=O)O4","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1803","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
artemyriantholide b
{"Ingredient_id": "HBIN016968","Ingredient_name": "artemyriantholide b","Alias": "NA","Ingredient_formula": "C30H36O6","Ingredient_Smile": "CC1=CCC23C1C4C(CCC2(O3)C)C5(CC6CC57C(=C6C)C8C(CCC7(C)O)C(=C)C(=O)O8)C(=O)O4","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1804","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
artemyriantholide d
{"Ingredient_id": "HBIN016970","Ingredient_name": "artemyriantholide d","Alias": "NA","Ingredient_formula": "C30H36O6","Ingredient_Smile": "CC1=CCC23C1C4C(CCC2(O3)C)C5(CC67C=CC5(C6C8C(CCC7(C)O)C(=C)C(=O)O8)C)C(=O)O4","Ingredient_weight": "492.6 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1806","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "21668651","DrugBank_id": "NA"}
(1s,10r,14s,17r,18s,19r,21r,22s)-5',9,9,14,18-pentamethyl-3'h-8,20,24-trioxaspiro[hexacyclo[19.2.1.0²,¹³.0⁴,¹⁰.0¹⁴,²².0¹⁷,²²]tetracosane-19,2'-pyran]-2(13),3,5-triene-6',7-dione
(2s)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-[(2e,6e)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-2,3-dihydro-1-benzopyran-4-one
(3s)-3-{5-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-2,4-dihydroxyphenyl}-5,7-dihydroxy-6-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
(3e,5s,7r,8r,10r,11r,12r,15r,16s,18e,25s)-11-acetyl-2,20,27-trihydroxy-10-methyl-21,26-diazapentacyclo[23.2.1.0⁵,¹⁶.0⁷,¹⁵.0⁸,¹²]octacosa-1,3,13,18,20,26-hexaen-28-one
3,6-dibenzyl-8-hydroxy-4,9,11-trimethyl-12-propyl-1-oxa-4,7-diazacyclododec-7-ene-2,5,10-trione
1,6,12,13-tetrahydroxy-3-(1h-indol-3-ylmethyl)-4,5,10-trimethyl-3h,3ah,6h,6ah,9h,10h,11h,12h,13h,14h-cycloundeca[d]isoindol-15-one
(2r)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-8-[(2r)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl]-6-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
4-hydroxy-2-(2-hydroxy-5-methylhexan-2-yl)-2-methyl-5-(3-methylbutanoyl)-9-phenyl-3h-furo[2,3-f]chromen-7-one
(3s,3ar,6s,6ar,10s,12r,13r,15as)-1,6,12,13-tetrahydroxy-3-(1h-indol-3-ylmethyl)-4,5,10-trimethyl-3h,3ah,6h,6ah,9h,10h,11h,12h,13h,14h-cycloundeca[d]isoindol-15-one
(2s)-2-{[(2s)-2-{[(2s)-2-{[(2s)-2-amino-3-carboxy-1-hydroxypropylidene]amino}-1-hydroxy-4-methylpentylidene]amino}-1-hydroxy-3-phenylpropylidene]amino}-3-methylbutanoic acid
(2s)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-8-[(2s)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl]-6-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
(1r,1'r,2r,3's,5s,6's,9s,10s,10's,11r,11'r,12s)-2-hydroxy-2,3',11,12'-tetramethyl-6-methylidene-2',8,9'-trioxaspiro[tetracyclo[9.2.2.0¹,¹⁰.0⁵,⁹]pentadecane-12,7'-tetracyclo[9.3.0.0¹,³.0⁶,¹⁰]tetradecane]-12',14-diene-7,8'-dione
(2s)-2-(2,4-dihydroxyphenyl)-5,7-dihydroxy-8-[(2r)-5-methyl-2-(prop-1-en-2-yl)hex-4-en-1-yl]-6-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
(1s,1'r,2r,3's,5s,6's,9s,10's,11'r,12r,14r)-2-hydroxy-2,3',11,12'-tetramethyl-6-methylidene-2',8,9'-trioxaspiro[tetracyclo[10.2.1.0¹,¹⁰.0⁵,⁹]pentadecane-14,7'-tetracyclo[9.3.0.0¹,³.0⁶,¹⁰]tetradecane]-10,12'-diene-7,8'-dione
(2s)-2-[2-(3,7-dimethylocta-2,6-dien-1-yl)-3,4-dihydroxyphenyl]-5,7-dihydroxy-6-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
(2r,3r,12bs)-3-ethenyl-9-methoxy-2-({6-methoxy-9h-pyrido[3,4-b]indol-1-yl}methyl)-1h,2h,3h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizine
C31H32N4O2 (492.25251319999995)
(4s)-3,8,9-trihydroxy-4-[4-hydroxy-3-(hydroxymethyl)but-2-en-1-yl]-6-methyl-4,7-bis(3-methylbut-2-en-1-yl)anthracen-1-one
(5s)-5-{2-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-3,4-dihydroxyphenyl}-9-hydroxy-13,13-dimethyl-4,14-dioxatricyclo[8.4.0.0³,⁸]tetradeca-1,3(8),9-trien-7-one
(1r,2s,5r,13r,15r,18s,23s,24s)-13-hydroxy-1,6,6,20,24-pentamethyl-7,22-dioxahexacyclo[13.12.0.0²,¹³.0⁵,¹¹.0¹⁶,²⁵.0¹⁸,²³]heptacosa-9,11,16(25),19-tetraene-8,21,26-trione
11-acetyl-2,20,27-trihydroxy-10-methyl-21,26-diazapentacyclo[23.2.1.0⁵,¹⁶.0⁷,¹⁵.0⁸,¹²]octacosa-1,3,13,18,20,26-hexaen-28-one
(2'r,6'r,8''r)-5''-(2-hydroxyethyl)-2'-(hydroxymethyl)-2',6'',8''-trimethyl-4'-methylidene-7'-oxo-1',3',3'',4'',7'',9''-hexahydrodispiro[cyclopropane-1,5'-indene-6',2''-indeno[4,5-b]pyran]-8''-carboxylic acid
3-[5-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxyphenyl]-5,7-dihydroxy-6-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
methyl (2s,3r,4ar,12bs,14as,14bs)-3,10-dihydroxy-2,4a,6,9,12b,14a-hexamethyl-4,11-dioxo-1,3,5,13,14,14b-hexahydropicene-2-carboxylate
methyl (2s,3r,12bs,14as,14bs)-3,10-dihydroxy-2,4a,6,9,12b,14a-hexamethyl-4,11-dioxo-1,3,5,13,14,14b-hexahydropicene-2-carboxylate
2-[3-(3,7-dimethylocta-2,6-dien-1-yl)-4-hydroxyphenyl]-3,5,7-trihydroxy-8-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
(2r)-2-[3-(3,7-dimethylocta-2,6-dien-1-yl)-2,4-dihydroxy-5-(3-methylbut-2-en-1-yl)phenyl]-5,7-dihydroxy-2,3-dihydro-1-benzopyran-4-one
2-hydroxy-2,3',11,12'-tetramethyl-6-methylidene-2',8,9'-trioxaspiro[tetracyclo[10.2.1.0¹,¹⁰.0⁵,⁹]pentadecane-14,7'-tetracyclo[9.3.0.0¹,³.0⁶,¹⁰]tetradecane]-10,12'-diene-7,8'-dione
(3s,6s,9s,11s,12s)-3,6-dibenzyl-8-hydroxy-4,9,11-trimethyl-12-propyl-1-oxa-4,7-diazacyclododec-7-ene-2,5,10-trione
1,3-dimethyl 2,4-bis[4-hydroxy-3-(3-methylbut-2-en-1-yl)phenyl]cyclobutane-1,3-dicarboxylate
(3s,3ar,6s,6ar,10s,12r,13r,15ar)-1,6,12,13-tetrahydroxy-3-(1h-indol-3-ylmethyl)-4,5,10-trimethyl-3h,3ah,6h,6ah,9h,10h,11h,12h,13h,14h-cycloundeca[d]isoindol-15-one
5-[(s)-[(1ar,4r,4ar,7s,7as,7br)-4-hydroxy-1,1,4,7-tetramethyl-octahydrocyclopropa[e]azulen-7-yl](phenyl)methyl]-2,4,6-trihydroxybenzene-1,3-dicarbaldehyde
(2r)-2-[3,4-dihydroxy-5-(3-methylbut-2-en-1-yl)phenyl]-5,7-dihydroxy-6,8-bis(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
(2s)-2-[3,4-dihydroxy-5-(3-methylbut-2-en-1-yl)phenyl]-5,7-dihydroxy-6,8-bis(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
methyl 2-methyl-4,14,21,31-tetraazaoctacyclo[15.15.0.0²,¹⁴.0³,¹¹.0⁵,¹⁰.0¹⁹,³¹.0²⁰,²⁸.0²²,²⁷]dotriaconta-3(11),5,7,9,15,20(28),22,24,26-nonaene-16-carboxylate
C31H32N4O2 (492.25251319999995)
methyl 3,10-dihydroxy-2,4a,6,9,12b,14a-hexamethyl-4,11-dioxo-1,3,5,13,14,14b-hexahydropicene-2-carboxylate
(2s)-2-[2,4-dihydroxy-5-(3-methylbut-2-en-1-yl)phenyl]-5,7-dihydroxy-6,8-bis(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
(2s)-5,7-dihydroxy-2-[(2s)-8-hydroxy-2-methyl-2-(4-methylpent-3-en-1-yl)-3,4-dihydro-1-benzopyran-5-yl]-6-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
(1r,2s,4s,5s,6s,10r,11s,12r,15r,19s)-6-(furan-3-yl)-11-hydroxy-1,5,10,15-tetramethyl-18-oxo-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadeca-8,16-dien-4-yl 2-methylprop-2-enoate
2,4,6-trihydroxy-5-({4-hydroxy-1,1,4,7-tetramethyl-octahydrocyclopropa[e]azulen-7-yl}(phenyl)methyl)benzene-1,3-dicarbaldehyde
6-(furan-3-yl)-11-hydroxy-1,5,10,15-tetramethyl-18-oxo-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadeca-8,16-dien-4-yl 2-methylprop-2-enoate
2-[3-(3,7-dimethylocta-2,6-dien-1-yl)-4,5-dihydroxyphenyl]-5,7-dihydroxy-6-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
methyl (2s,3s,4ar,12bs,14as,14bs)-3,10-dihydroxy-2,4a,6,9,12b,14a-hexamethyl-4,11-dioxo-1,3,5,13,14,14b-hexahydropicene-2-carboxylate
5,7-dihydroxy-2-[8-hydroxy-2-methyl-2-(4-methylpent-3-en-1-yl)-3,4-dihydro-1-benzopyran-5-yl]-6-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
(2s)-2-{5-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-2,4-dihydroxyphenyl}-5,7-dihydroxy-8-(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
13-hydroxy-1,6,6,20,24-pentamethyl-7,22-dioxahexacyclo[13.12.0.0²,¹³.0⁵,¹¹.0¹⁶,²⁵.0¹⁸,²³]heptacosa-9,11,16(25),19-tetraene-8,21,26-trione
(2r)-2-{3-[(2e)-3,7-dimethylocta-2,6-dien-1-yl]-2,4-dihydroxy-5-(3-methylbut-2-en-1-yl)phenyl}-5,7-dihydroxy-2,3-dihydro-1-benzopyran-4-one
(3s)-3-[2,4-dihydroxy-5-(3-methylbut-2-en-1-yl)phenyl]-5,7-dihydroxy-6,8-bis(3-methylbut-2-en-1-yl)-2,3-dihydro-1-benzopyran-4-one
(5s,7r,8r,10r,11r,12r,15r,16s,25s)-11-acetyl-2,20,27-trihydroxy-10-methyl-21,26-diazapentacyclo[23.2.1.0⁵,¹⁶.0⁷,¹⁵.0⁸,¹²]octacosa-1,3,13,18,20,26-hexaen-28-one
methyl (2r,3s,4ar,12br,14ar,14bs)-3,10-dihydroxy-2,4a,6,9,12b,14a-hexamethyl-4,11-dioxo-1,3,5,13,14,14b-hexahydropicene-2-carboxylate
3-ethenyl-9-methoxy-2-({6-methoxy-9h-pyrido[3,4-b]indol-1-yl}methyl)-1h,2h,3h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizine
C31H32N4O2 (492.25251319999995)